Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin’s lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey [Corrigendum]

• Principais autores: Ponzetti C (Autor), Canciani M (Autor), Farina M (Autor), Era S (Autor), Walzer S (Autor)
• Formato: Livro
• Publicado em: Dove Medical Press, 2017-01-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Ponzetti C, Canciani M, Farina M, Era S, Walzer S. ClinicoEconomics and Outcomes Research. 2016;8:227–233.On page 230, Table 3, first column: The last time component should be: “Patient preparation time for eighteen cycles of therapy in oncology (breast cancer)”.&nb...